May 6, 2026 04:00PM
Feb 25, 2026 04:00PM
Jan 12, 2026 08:10AM
Jan 12, 2026 08:00AM
Nov 17, 2025 08:04AM
Nov 17, 2025 08:00AM
Aug 6, 2025 04:00PM Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
Jun 26, 2025 08:00AM
Jun 10, 2025 08:00AM
Jun 9, 2025 06:40AM
Jun 6, 2025 08:00AM
May 7, 2025 11:19AM
May 7, 2025 11:18AM
May 6, 2025 04:00PM Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Mar 7, 2025 08:00AM
Feb 28, 2025 09:00AM
Feb 26, 2025 08:02AM
Feb 26, 2025 08:00AM
Feb 25, 2025 04:00PM
Nov 6, 2024 04:00PM
Sep 24, 2024 08:00AM Arcutis Biotherapeutics (ARQT): FDA Accepts NDA Application for ZORYVE Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
Sep 24, 2024 08:00AM
Jul 9, 2024 08:43AM
Jul 9, 2024 08:00AM
Jun 10, 2024 02:31PM
Jun 10, 2024 02:30PM
May 15, 2024 07:15AM
May 14, 2024 04:00PM Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
Mar 10, 2024 04:00PM
Feb 27, 2024 05:50AM
Jan 16, 2024 05:19AM
Jan 14, 2024 04:00AM
Nov 29, 2023 08:02AM
Nov 29, 2023 08:00AM
Apr 18, 2023 08:02AM Arcutis Biotherapeutics (ARQT) Announces FDA Acceptance of NDA for Roflumilast Foam
Apr 18, 2023 08:00AM
Apr 18, 2023 08:00AM
Jul 7, 2022 06:15AM
Jun 6, 2022 08:41AM
Jun 6, 2022 07:30AM
Jun 6, 2022 07:30AM
Jun 6, 2022 07:30AM Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
May 5, 2022 04:01PM
May 5, 2022 04:01PM
Mar 28, 2022 10:28AM
Mar 28, 2022 08:00AM
Mar 28, 2022 08:00AM
Mar 25, 2022 07:31AM
Mar 25, 2022 07:31AM Arcutis Biotherapeutics Inc. (ARQT) Reports Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study
Mar 25, 2022 07:30AM

15,464 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All